This will take effect August 4, 2014
Overview and Clinical Utility:
To improve performance and sensitivity of the Toxoplasma assay, PathGroup Labs will begin testing by Chemiluminescent Immunoassay for IgM Antibodies. The serological diagnosis of acute toxoplasmosis allows adequate treatment which reduces the risks of the disease both in immunocompromised patients and pregnant women.
Click Here to read more.